Pharmaceutical companies would have to spend a lot of money on pediatric anticoagulation studies for diseases that are rare among these patients, explained Michael A. Portman, MD, FAHA, of Seattle Children's Hospital.
Pharmaceutical companies would have to spend a lot of money on pediatric anticoagulation studies, for diseases that are rare among these patients, and the statistical methods differ as well for adult studies, explained Michael A. Portman, MD, FAHA, director, Pediatric Cardiovascular Research, Center for Integrative Brain Research, and professor of pediatrics at Seattle Children's Hospital and the University of Washington in Seattle.
Transcript
Why have there been few studies on the use of pediatric anticoagulation?
I think it’s most due to the interest [from] the pharmaceutical companies and spending the money. They would have to spend a lot of money on relatively few patients who would take their medications. So for this study, we were really fortunate in that Daiichi Sankyo sponsored the study. We enrolled quite a few patients for a pediatric study; we had, I believe, 168 patients enrolled—so that's pretty large for a pediatric study. In contrast, for an adult study, you would have thousands of patients. So there are difficulties even when the drug company sponsors [a study]; there is a rarity of the patients, because these are rare diseases. And most of the companies and actually the FDA demands certain statistical methods. And you really can't use those statistical methods in children because of the rarity of the diseases. So that's another barrier, the type of information that the FDA requires for approval of those drugs, although I think they're becoming more lenient, understanding that we can't use adult type trial design in children.
OptumRx’s Jon Mahrt Discusses “Irresponsible” Drug Pricing for Products With Multiple Indications
April 30th 2024When the same product comes to market with additional indications, irrational pricing decisions result in ever increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More